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The effectiveness of colorectal cancer (CRC) screening programs is directly related to par-
ticipation and the number of interval CRCs. The objective was to analyse specific-mortality
in a cohort of individuals invited to a CRC screening program according to type of CRC diag-
nosis (screen-detected cancers, interval cancers, and cancers among the non-uptake
group).
Material and methods
Retrospective cohort that included invitees aged 50–69 years of a CRC screening program
(target population of 85,000 people) in Catalonia (Spain) from 2000–2015 with mortality fol-
low-up until 2020. A screen-detected CRC was a cancer diagnosed after a positive faecal
occult blood test (guaiac or immunochemical); an interval cancer was a cancer diagnosed
after a negative test result and before the next invitation to the program (�24 months); a
non-uptake cancer was a cancer in subjects who declined screening.
Results
A total of 624 people were diagnosed with CRC (n = 265 screen-detected, n = 103 interval
cancers, n = 256 non-uptake). In the multivariate analysis, we observed a 74% increase in
mortality rate in the group with interval CRC compared to screen-detected CRC adjusted for
age, sex, location and stage (HR: 1.74%, 95% CI:1.08–2.82, P = 0.02). These differences
were found even when we restricted for advanced-cancers participants. In the stratified
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analysis for type of faecal occult blood test, a lower mortality rate was only observed among
FIT screen-detected CRCs.
Conclusion
CRC screening with the FIT was associated with a significant reduction in CRC mortality.
Introduction
Faecal occult blood test (FOBT) screening followed by a colonoscopy has been demonstrated
to decrease colorectal cancer (CRC) mortality [1] and has been implemented in most devel-
oped countries as the preferable method for CRC screening [2, 3]. Population-screening pro-
grams aim to reduce CRC mortality thorough early detection [4]. For this reason, it is
important to detect the largest number of existing tumours in the population before their clini-
cal occurrence. Additionally, FOBTs can detect some preneoplastic polyps that can be
removed during colonoscopy, thereby reducing the incidence of cancer [2]. To achieve this
goal, the screening program needs to be well organized and requires high uptake. Participation
rates in population-based organized CRC screening programmes vary widely across countries
[5]. A higher participation rate is observed in FOBT screening than colonoscopy [6], especially
among subjects invited to faecal immunochemical test (FIT) screening compared to those
invited to guaiac faecal occult blood test (gFOBT) screening [7].
Screening attempts to detect early-stage cancers to achieve a better prognosis and improved
mortality. Consequently, the monitoring of interval cancers is a key performance indicator of
an organized population-based screening programme and provides a mechanism to evaluate
the impact of the program on CRC mortality in the target population. In a CRC screening pro-
gramme, there are three distinct categories of cancer diagnoses. The non-uptake cancers
(those among individuals who decline the screening test and are later diagnosed with a CRC),
interval cancers (a cancer detected after a negative FOBT and before the next invitation is due
[8]) and screen-detected cancers. Interval cancers may either be due to a false-negative FOBT
result or fast-growing (high microsatellite instability and CpG island methylator phenotype
(CIMP)-high) [9] tumours that have developed between screening rounds. Consequently, the
effectiveness of the program also depends on the ability of the screening test to detect cancers.
The gFOBT has been replaced by the FIT because of its higher sensitivity and specificity [2, 5,
10, 11]. However, the FIT, as a screening test, has a sensitivity of 86% to detect CRC [1] so
interval cancers are inevitable but their number should be as small as possible to ensure screen-
ing effectiveness.
The aim of the study was to quantify the impact on mortality of identifying CRCs through
screening compared to interval cancer. We also aimed to compare differences in CRC mortal-
ity in clinical-detected cases (interval cancers versus non-uptake cancers).
Materials and methods
Briefly, Catalan Institute of Oncology (Barcelona) manages a free, public, biennial screening
programme using FOBT. From 2000–2010, the gFOBT was used as the screening test (Hema-
screenTM). In 2010, the FIT with a cut-off of�20μg Hb/g faeces (100 ng/mL) (OC-Sensor,
Eiken Chemical Co., Japan) replaced the gFOBT as the screening test of choice.
The CRC screening program was launched as a pilot program and was considered an estab-
lished program by the third round. The median time between invitations was 33 months in the
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firsts rounds with gFOBT due to organizational and management constraints. However, in
subsequent rounds with the FIT the median time between screening invitations was 24
months.
The target population of the current study (n = 85,000 approximately) includes all men and
women aged 50–69 years from l’Hospitalet de Llobregat, Vilafranca del Penedès and Penedès
rural (Barcelona, Catalonia, Spain). Exclusion criteria of the screening programme are as fol-
lows: gastrointestinal symptoms, familial or personal history of CRC, hereditary CRC syn-
dromes, prior adenomas, or inflammatory bowel disease, colonoscopy in the previous five
years or an FOBT within the last two years, terminal disease and severe disabling conditions.
Individuals with an invalid mailing address were also excluded. A detailed description of the
programme and its quality indicators has been previously described [12, 13].
The study period was from May 2000 to December 2015 with a minimum vital status fol-
low-up of 36 months. The following variables were taken into account in the analysis: sex, age,
area-level deprivation, type of FOBT, type of participation (first invitation or successive), num-
ber of screening participations, date of CRC diagnosis, details of CRC (location, morphology,
TNM staging (8th edition) classified as early (TNM I/II) or advanced (TNM III/IV) stage), and
vital status that was identified through the Population Death Register until 1 August 2020. The
deprivation level was calculated for primary healthcare areas of the Catalan territory [14]. It is
a score index that uses aggregated indicators of income, employment, health, disability and
education to generate a scale from 0 (least deprived) to 100 (most deprived). The scores were
recoded into terciles to enable comparisons between individuals living in the most and least
deprived area.
The CRC screening programme information system allowed recording: FIT result, number
of individual participations, screening test (guaiac or immunochemical), final screening test
results (positive, negative, or indeterminate), and colonoscopy findings. Then, this informa-
tion was linked with the minimum basic set of hospital discharge data (CMBD-AH), which
contains information on procedures and diagnoses for each hospital admission of public hos-
pitals of Catalonia and has reasonable accuracy to identify cancer cases [15]. The two databases
were linked to allow classification of subjects into their respective groups of screened-detected,
interval, and non-uptake. Participation was defined as having a conclusive FOBT result. All
the participants were followed until December 2015 to identify whether they were diagnosed
after a FOBT with a CRC (International Classification of Diseases 10th Revision [ICD-10]:
C18, C19 and C20: colon or rectum). We did an exhaustive chart review where we went
through colonoscopy and surgical reports as well as admission notes to confirm the classifica-
tion of these individuals, and to recollect study covariates and cause of death.
The CRCs were identified and classified into: 1) Screen-detected cancer: a cancer detected
after a positive FOBT (guaiac and immunochemical); 2) Interval cancer: a cancer diagnosed
after a negative FOBT result and before the next scheduled screening invitation(8) (�24
months); 3) Non-uptake cancers: a cancer in subjects who were invited to the screening, but
did not participate in it. Although the next scheduled screening was defined to be 24 months
after the previous screen, the interval between screening invitations was higher in the earlier
rounds with gFOBT. We have performed a sensitivity analysis in gFOBT participants defining
interval cancers as those diagnosed�30 months after the last gFOBT and no differences were
observed (see S1 Table and S1 Fig in S1 File)
There were an additional 33 diagnoses of CRC after a FIT positive result (post-colonoscopy
CRC); 1 case diagnosed before the first participant’s invitation, 2 diagnoses in subjects with
inherited CRC syndromes, and 208 were diagnosed more than 24 months after screening
FOBT analysis (individuals with a negative FOBT result who did not participate in successive
screening); these diagnoses were excluded from the analysis.
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The location of the CRC was defined according to its anatomic distribution: proximal, dis-
tal, and rectum. CRCs diagnosed in the cecum, ascending colon, hepatic flexure and transverse
colon were considered proximal or right-sided. Distal or left-sided cancers were those diag-
nosed in the splenic flexure, the descending colon, sigmoid colon and the recto-sigmoid junc-
tion. Anal and appendix cancers were excluded.
Our CRC screening programme follows the Public Health laws and the Organic Law on
Data Protection. All procedures performed in the study involving data from human partici-
pants were in accordance with the ethical standards of the institutional research committee,
and with the 1964 Helsinki Declaration and its later amendments or comparable ethical stan-
dards. No informed consent was requested to the participating individuals, since this study
was based on anonymized data routinely collected. The study protocol was approved by the
Ethics Committee for Clinical Research (PR234/16).
Exact test of Fisher or χ2-test were used for categorical variables and 2 categories t-test or
the non-parametric Mann Whitney U test were used for quantitative variables. Overall mortal-
ity after CRC diagnosis was compared by Kaplan-Meier estimation, long-rank test and Cox
proportional hazard ratios to date of death or censoring resulting from the end of the study
period (1 August 2020). In the survival analysis, non-CRC deaths or unknown cause of death
(n = 6) were censored. We performed a sensitivity analysis in participant subjects (screening
and interval groups) to correct for lead-time bias. In this analysis the survival time was mea-
sured from the date of the last FOBT performed to date of death or censoring. Statistical analy-
sis was carried out using R statistical software (R Foundation for Statistical Computing,
Vienna, Austria).
Results
Within the study period of 1 May 2000 to 31 December 2015, 539.475 individuals were invited,
with an uptake rate that increased from 17.2% in the first round to 45.8% in the last one. Fig 1
presents a flowchart of the population examined, from when they were invited to perform the
FOBT to when they were diagnosed with CRC.
A total of 624 people were diagnosed with CRC within the age range (50–69 years) eligible
for screening plus 24 months. Of these, 265 (42.5%) were screen-detected, 103 (16.5%) were
interval cancers, 256 (41.0%) were diagnosed in individuals who were invited but did not par-
ticipate (non-uptake group). Interval cancers were detected in�12 months of the FOBT per-
formance in 33.0% of the cases (n = 34) and 67.0% (n = 69) of them were diagnosed after 12
months.
Comparison of all the subgroups of colorectal cancers
Table 1 shows the patients’ characteristics as well as the characteristics of the tumour in terms
of the location, histologic type, and stage. The 5-year mortality in CRC was 11.8% (95% CI;
7.8–15.7) in screen-detected group, 25.1% (95% CI; 16.1–33.2) in interval group and 34.8%
(95% CI; 28.8–40.8) in non-uptake group. With a mean follow-up of 81.2 (SD = 51.6) months
across the population, the number of patients who died of CRC was 166 (79.4%) and 37
(17.7%) of other causes.
When comparing the three CRC groups, we observed a 67% (95% CI; 1.04–2.70) increase
in mortality rate in the CRC interval group and a two-fold risk (95% CI; 1.51–3.30) of mortal-
ity in the non-uptake group compared to the screen-detected CRC adjusted for sex, age, socio-
economic index, location, and TNM stage (Fig 2). Male sex and advanced stage were
independent predictors of a higher mortality rate (Fig 2).
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Participants (screen-detected or interval) vs non-uptake group
Among the non-uptake individuals there were more males than among participants. In fact,
there were 128 women in the participants’ group (34.8%) and 68 in the non-uptake group
(26.6%) (p = 0.04). When compared with the non-uptake group, the participants group were
more staged I (35.4% vs 8.44%) and less staged IV (14.1% vs 29.1%) with no differences regard-
ing area-level deprivation, location, and histologic type (Table 1). When these two groups were
compared against each other, the non-uptake group had an 84% higher risk of mortality (HR:
1.84%, 95% CI: 1.32–2.55, P = 0.0003) (Table 2).
Screen-detected vs interval group
When compared with the screen-detected group, interval CRCs were associated with succes-
sive screening, gFOBT as the last type of test performed before the diagnoses, rectum and
proximal location, advanced TNM stage, and death for CRC, with no differences in sex, age,
area-level deprivation, and histologic type (Table 1). It is important to highlight that 41.1% of
the screen-detected CRCs were stage I. Among the participants, higher mortality rates were
Fig 1. Colorectal cancers for the 2000–2015 invitee study group. aColorectal cancer diagnoses>24 months after FOBT analysis were excluded from the
analysis. FOBT: faecal occult blood test; gFOBT: guaiac faecal occult blood test; FIT: faecal immunochemical test.
https://doi.org/10.1371/journal.pone.0253369.g001
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observed among patients with interval cancers (HR: 1.74%, 95% CI:1.08–2.82, P = 0.02)
(Table 2) than with screen-detected cancers. Interaction analysis between screen-detected
Table 1. Characteristics of colorectal cancer according to type of detection.
Screen-detected Interval Non-uptake Screen vs Interval Interval vs Non-uptake Participantsa vs Non-uptake
n = 265 n = 103 n = 256 P-value P-value P-value
Sex 1.00 0.14 0.037
Female 92 (34.7%) 36 (35.0%) 68 (26.6%)
Male 173 (65.3%) 67 (65.0%) 188 (73.4%)
Age at diagnosis (mean (SE), years) 61.9 (5.5) 62.7 (5.0) 63.3 (5.6) 0.17 0.33 0.008
Age at diagnosis (years) 0.09 0.64 0.336
50–59 90 (34.0%) 25 (24.3%) 70 (27.3%)
60–72 175 (66.0%) 78 (75.7%) 186 (72.7%)
Socioeconomic Score 0.25 0.01 0.027
0–39 (least deprived) 10 (3.77%) 1 (0.97%) 11 (4.30%)
39–51 80 (30.2%) 27 (26.2%) 98 (38.3%)
52–100 (most deprived) 175 (66.0%) 75 (72.8%) 147 (57.4%)
Last participation <0.001 NA NA
Initial 191 (72.1%) 43 (41.7%) NA
Successive 74 (27.9%) 60 (58.3%) NA
Type of last FOBT <0.001 NA NA
gFOBT 190 (71.7%) 41 (39.8%) NA
FIT 75 (28.3%) 62 (60.2%) NA
Tumour Location 0.001 0.19 0.340
Distal 140 (52.8%) 34 (33.0%) 110 (43.0%)
Proximal 61 (23.0%) 27 (26.2%) 57 (22.3%)
Rectum 59 (22.3%) 40 (38.8%) 82 (32.0%)
Missing 5 (1.9%) 2 (1.9%) 7 (2.7%)
Histologic type 0.10 0.89 0.213
Adenocarcinoma 180 (67.9%) 62 (60.2%) 192 (75.0%)
Mucinous 7 (2.6%) 5 (4.9%) 17 (6.6%)
Others 2 (0.8%) 3 (2.9%) 7 (2.7%)
Missing 76 (28.7%) 33 (32.0%) 40 (15.6%)
TNM Stage <0.001 0.04 <0.001
I 109 (41.1%) 19 (18.4%) 20 (7.8%)
II 54 (20.4%) 23 (22.3%) 62 (24.2%)
III 72 (27.2%) 34 (33.0%) 86 (33.6%)
IV 28 (10.6%) 23 (22.3%) 69 (27.0%)
Missing 2 (0.8%) 4 (3.9%) 19 (7.4%)
TNM Stage 0.001 0.22 <0.001
I-II 163 (61.5%) 42 (40.8%) 82 (32.0%)
III-IV 100 (37.7%) 57 (55.3%) 155 (60.5%)
Missing 2 (0.8%) 4 (3.9%) 19 (7.4%)
Death for CRC 0.001 0.41 <0.001
No 224 (84.5%) 71 (68.9%) 163 (63.7%)
Yes 41 (15.5%) 32 (31.1%) 93 (36.3%)
aParticipants includes individuals with screen-detected cancers and interval cancers.
SE: standard error; FOBT: faecal occult blood test; gFOBT: guaiac faecal occult blood test; FIT: faecal immunochemical test; CRC: colorectal cancer; NA: not applicable.
https://doi.org/10.1371/journal.pone.0253369.t001
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Fig 2. Multivariate analyses for colorectal cancer mortality comparing all the invitee study group. aHazard ratios adjusted by
the variables shown in this figure. CRC: colorectal cancer.
https://doi.org/10.1371/journal.pone.0253369.g002
Table 2. Multivariate analyses for colorectal cancer mortality according to type of detection.
SC vs IC vs NC SC vs IC IC vs NC PC vs NC
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Sex
Female 1.00 1.00 1.00 1.00
Male 1.57 1.07–2.30 1.79 1.05–3.05 1.42 0.91–2.20 1.57 1.07–2.30
Age at diagnosis 1.00 0.97–1.00 1.00 0.95–1.04 1.00 0.97–1.00 1.00 0.97–1.03
Socioeconomic index 1.00 0.98–1.00 1.00 0.98–1.03 1.99 0.98–1.00 1.00 0.98–1.01
Tumour location
Distal 1.00 1.00 1.00 1.00
Proximal 1.40 0.95–2.10 1.19 0.68–2.09 1.43 0.88–2.30 1.43 0.97–2.12
Rectum 0.88 0.60–1.30 0.54 0.29–0.98 1.15 0.75–1.80 0.91 0.62–1.32
CRC group
Screening 1.00 1.00 NA 1.00
Interval 1.67 1.04–2.70 1.74 1.04–2.91 1.00
Non-uptake 2.23 1.51–3.30 NA 1.32 0.89–2.00 1.84 1.32–2.55
TNM stage
I-II 1.00 1.00 1.00 1.00
III-IV 7.33 4.55–11.80 8.95 4.65–17.23 5.95 3.33–10.60 7.68 4.77–12.36
SC: screen-detected colorectal cancers; IC: interval cancers: NC: cancers in the non-uptake group; PC: cancers in the group of participants (includes individuals with
screen-detected and interval cancers; HR: hazard ratio; CRC: colorectal cancer; NA: not applicable.
Associations with p<0.05 are shown in bold.
https://doi.org/10.1371/journal.pone.0253369.t002
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colorectal cancers and interval cancers according with the TNM stage is shown in Table 3. A
higher mortality rate in the group of interval cancer with early stage compared to the screening
group with the same stage was observed. The S2 Fig in S1 File displays the Kaplan–Meier
curves of screen-detected cancers and interval cancers stratified for early (stage I-II) and
advanced (stage III-IV). After considering for the lead-time bias, the hazard ratio for interval
CRCs was not significant (HR: 1.55, 95% CI:0.96–2.50, P = 0.08).
Interval vs non-uptake group
When compared with the non-uptake group, the interval cancer group were more likely to live
in a more socioeconomically deprived area and to be diagnosed with a staged I cancer. How-
ever, no differences in mortality were found (Table 2).
Stratified analysis according to screening test (gFOBT vs FIT)
The characteristics of the participants in the screening programme according to the type of last
FOBT performed are shown in Table 4. Successive screening with any FOBT was associated
with interval cancer. We observed a differential distribution in the location of the tumour. Dis-
tal location was the most frequent in screened-cancers specially with gFOBT. There was a sig-
nificant difference in mortality among interval cancers when using the FIT (Fig 3) but not for
gFOBT participants (S1A and S1B Fig in S1 File). CRC mortality among FIT participants was
11.2% (95% CI; 6.6–15.6) in screen-detected group and 27.2% (95% CI; 12.0–39.7) in interval
group. These differences were found even when restricting for advanced-cancers (Table 3) and
after considering for lead-time bias (HR: 2.30, 95% CI: 1.06–5.01, P = 0.04).
Discussion
In this population-based CRC screening programme study, of the 624 cancers diagnosed in
the group offered screening, 265 (42.5%) were detected by FOBT screening, 103 (16.5%) pre-
sented after a negative FOBT and before the next invitation, and 256 (41.0%) presented in the
non-uptake group.
Table 3. Interaction analysis between screen-detected colorectal cancers and interval cancer and TNM stage.
Participants in FOBT screening
Adjusted ORa 95% CI
Interval CRC–Stage III-IV 1.00
Screened-detected CRC–Stage III-IV 0.61 0.37–1.02
Interval CRC–Stage I-II 0.16 0.05–0.44
Screened-detected CRC–Stage I-II 0.06 0.03–0.13
Participants in FIT screening
Adjusted ORa 95% CI
Interval CRC–Stage III-IV 1.00
Screened-detected CRC–Stage III-IV 0.34 0.15–0.77
Interval CRC–Stage I-II 0.05 0.01–0.42
Screened-detected CRC–Stage I-II 0.03 0.01–0.09
aAdjusted by sex, age, socioeconomic score, and location.
FOBT: faecal occult blood test (guaiac or immunochemical); FIT: faecal immunochemical test; CRC: colorectal
cancer.
https://doi.org/10.1371/journal.pone.0253369.t003
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Our results confirmed the positive impact of screening on CRC mortality risk specially with
the implementation of the FIT. When compared with the screen-detected group, the risk of
CRC death was 68% higher in the group with interval CRC and a two-fold risk of mortality
was observed in the non-uptake group. Around 40% of all screen-detected cancers were diag-
nosed at stage I which adds support to the mortality findings. This difference in mortality rate
was found when comparing the participants (screening vs interval) but not when the interval
group was compared with the non-uptake group.
Table 4. Characteristics of colorectal cancer among participants according to type of faecal occult blood test.
g-FOBT FIT
Screening Interval P-value Screening Interval P-value
n = 75 n = 62 n = 190 n = 41
Sex 0.96 1.000
Female 24 (32.0%) 21 (33.9%) 68 (35.8%) 15 (36.6%)
Male 51 (68.0%) 41 (66.1%) 122 (64.2%) 26 (63.4%)
Age at diagnosis (median (SE), years) 61.7 (5.03) 62.7 (4.99) 0.26 62.0 (5.65) 62.8 (5.10) 0.38
Socioeconomic Score 0.62 0.69
0–39 (least deprived) 0 (0.0%) 0 (0.0%) 10 (5.26%) 1 (2.44%)
39–51 17 (22.7%) 11 (17.7%) 63 (33.2%) 16 (39.0%)
52–100 (most deprived) 58 (77.3%) 51 (82.3%) 0.62 117 (61.6%) 24 (58.5%)
Last participation 0.004 <0.001
Initial 50 (66.7%) 25 (40.3%) 141 (74.2%) 18 (43.9%)
Successive 25 (33.3%) 37 (59.7%) 49 (25.8%) 23 (56.1%)
Number of FOBT participations 0.013 0.001
1 50 (66.7%) 25 (40.3%) 141 (74.2%) 18 (43.9%)
2 12 (16.0%) 22 (35.5%) 37 (19.5%) 17 (41.5%)
3 10 (13.3%) 12 (19.4%) 12 (6.3%) 6 (14.6%)
4 3 (4.0%) 3 (4.8%) NA NA
Tumour Location 0.008 0.04
Distal 45 (60.0%) 22 (35.5%) 95 (50.0%) 12 (29.3%)
Proximal 15 (20.0%) 12 (19.4%) 46 (24.2%) 15 (36.6%)
Rectum 15 (20.0%) 26 (41.9%) 44 (23.2%) 14 (34.1%)
Missing 0 (0.0%) 2 (3.2%) 5 (2.6%) 0 (0.0%)
TNM Stage 0.03 0.05
I 28 (37.3%) 9 (14.5%) 81 (42.6%) 10 (24.4%)
II 15 (20.0%) 13 (21.0%) 39 (20.5%) 10 (24.4%)
III 22 (29.3%) 23 (37.1%) 50 (26.3%) 11 (26.8%)
IV 10 (13.3%) 14 (22.6%) 18 (9.5%) 9 (22.0%)
Missing 0 (0.0%) 3 (4.8%) 2 (1.1%) 1 (2.4%)
TNM Stage 0.03 0.15
I-II 43 (57.3%) 22 (37.3%) 120 (63.2%) 20 (48.8%)
III-IV 32 (42.7%) 37 (62.7%) 68 (35.8%) 20 (48.8%)
Missing 0 (0.0%) 3 (4.8%) 2 (1.1%) 1 (2.4%)
Death for CRC 0.38 0.01
No 57 (76.0%) 42 (67.7%) 167 (87.9%) 29 (70.7%)
Yes 18 (24.0%) 20 (32.3%) 23 (12.1%) 12 (29.3%)
SE: standard error; FOBT: faecal occult blood test; gFOBT: guaiac faecal occult blood test; FIT: faecal immunochemical test; CRC: colorectal cancer; NA: not applicable.
https://doi.org/10.1371/journal.pone.0253369.t004
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No randomized trial has been carried out on CRC screening using the FIT and the impact
of the use of this test derives from observational studies with FIT and randomized trials with
gFOBT [16–22]. However, there is sufficient evidence that the FIT meaningfully impact on
CRC incidence and mortality [4, 11]. A recent systematic-review [23] has compared the mor-
tality effect of CRC FOBT-screening (11 studies of gFOBT and 2 studies of FIT) across Euro-
pean regions. Among individuals invited to screening, CRC mortality was a 12% lower using
the gFOBT and 36% lower when using FIT compared to those not invited. In our study, a
higher reduction in mortality was achieved with the use of the FIT as a screening test as differ-
ences were found even when restricting for advanced-cancers and after considering lead-time
bias. By contrast, the stratified analysis with gFOBT did not show an improved mortality rate
among screen-detected CRCs.
There are two recent reviews that compare screen-detected versus FOBT interval cancer [9,
24]. First, Wieten et al. [24] published a systematic review and meta-analysis to evaluate the
incidence rates of interval CRC following gFOBT and FIT in population-based CRC screening
programmes. They reported a lower incidence rate of interval cancer after a negative FIT than
after the gFOBT (20 vs 34 interval CRCs per 100,000 person-years, respectively). Afterwards,
our group performed a review [9] focused only in FIT-based population screening and found
that the interval CRC proportion was around 15% and that interval cancers were more fre-
quent in women and in the right colon and were staged more advanced. In this study, the find-
ings are consistent with the literature as the interval cancer proportion was 45.3% for gFOBT
and 17.7% for FIT. And, when compared with the screen-detected group, interval CRCs were
associated with rectum and proximal location and advanced TNM stage. Two Spanish investi-
gations [25, 26] also reported an increased incidence of interval CRC located in the rectum.
The FIT was better at detecting cancers in the distal colon; however, the mortality effect of the
Fig 3. Multivariate analyses for colorectal cancer mortality in FIT participants. aHazard ratios adjusted by the variables shown
in this figure. CRC: colorectal cancer.
https://doi.org/10.1371/journal.pone.0253369.g003
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FIT was similar regardless of the tumour location. In fact, a meta-analysis study reported that
the FIT sensitivity for detecting CRC located in the distal colon was comparable to that in the
proximal colon [27].
This reduction in mortality is in accordance with few studies that that have analysed the
effect of the FIT in participants vs non-participants. Ventura et al. [28] observed a reduction in
CRC mortality of 41% for participants as compared to non-uptakers. Idigoras et al. [26]
reported a 5-year survival rate of 90.1% in screen-detected group, 76.3% in interval group and
60.5% in non-uptake group (P =<0.001). Corrado et al. [29] found an average overall survival
in non-uptakers of 60.5%, whereas for participants, the overall survival was 85.1% (P = 0.001).
Among the participating subjects, patients with interval cancers had worse overall survival
rates (68.5%) than patients with screen-detected cancers (87.0%, P = 0.001).
Although we did not observe a higher frequency of CRC among men, male had a higher
CRC mortality than women consistent with previous research [30]. However, our findings
may be somewhat limited by the lack of information of patient comorbidities and received
treatments. In our study population, men were older than women (p = 0.004) but we did not
observe differences in the socioeconomic index, type of CRC detection, or tumour location.
Another limitation of the study is that we were not able to assess the values of the faecal hae-
moglobin of the FIT with a negative result prior to the diagnosis of interval cancer. By contrast,
a strength of the study is the chart review performed to decrease misclassification of any partic-
ipant or covariate analysed. Another strength is that we analysed a real-life scenario of a
screening programme which undergoes a change of test. We have compared the impact on
mortality of the use of the gFOBT and the FIT in the same screening population.
The current study data indicate that, with a participation rate of less than 50%, a reduction
in mortality rates is achievable with FIT screening. This study shows how essential is achieving
a high participation rate in the screening programme. Moreover, it is very important to ensure
that people complete the screening process (having a conclusive FOBT result and completing
colonoscopy after a positive FOBT) [31].
The group of interval cancers comprise a significant number of participants falsely reas-
sured by their results. We should better inform our participants to carefully monitor the symp-
toms despite having a recent negative FOBT result.
In conclusion, our study confirms that there are differences in mortality according to the
type of detection specially when using the FIT and these differences are not only explained by
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